α-Substituted Malonester Amides: Tools To Define the Relationship between ACAT Inhibition and Adrenal Toxicity
作者:Drago R. Sliskovic、Joseph A. Picard、Patrick M. O'Brien、Peggy Liao、W. Howard Roark、Bruce D. Roth、Maureen A. Anderson、Sandra Bak Mueller、Thomas M. A. Bocan、Richard F. Bousley、Katherine L. Hamelehle、Reynold Homan、James F. Reindel、Richard L. Stanfield、Daniel Turluck、Brian R. Krause
DOI:10.1021/jm970560h
日期:1998.2.1
evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyl transferase activity in vitro and to lower plasma total cholesterol levels in a variety of cholesterol-fed animal models. Compounds of this series were also useful in examining the relationship between adrenal toxicity and ACAT inhibition. One compound from this series, 9f, was a potent inhibitor of ACAT in both the microsomal and cellular
我们制备了一系列的α-取代的马诺酯酰胺,评估了它们在体外抑制酰基辅酶A:胆固醇O-酰基转移酶活性并降低各种胆固醇喂养的动物模型中血浆总胆固醇水平的能力。该系列化合物还可用于检查肾上腺毒性和ACAT抑制之间的关系。在微粒体和细胞测定中,该系列的一种化合物9f是ACAT的有效抑制剂。如通过生物测定和HPLC-UV测定所确定的,其也是生物可利用的。在豚鼠和狗的肾上腺毒性模型中均对该化合物进行了评估,并与四唑酰胺15进行了比较。然而,化合物9f导致肾上腺坏死,而化合物15对肾上腺无作用。这增加了越来越多的证据表明,用ACAT抑制剂观察到的肾上腺毒性可能与机制无关。